

# Nicolas Mounier

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2733508/nicolas-mounier-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

161  
papers

10,417  
citations

54  
h-index

100  
g-index

173  
ext. papers

11,831  
ext. citations

4.3  
avg, IF

5.11  
L-index

#	Paper	IF	Citations
161	Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study. <i>Annals of Hematology</i> , <b>2021</b> , 1	3	0
160	Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2161-2168	1.9	2
159	Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas. <i>Aids</i> , <b>2021</b> , 35, 861-868	3.5	2
158	Cancer incidence in the vicinity of a waste incineration plant in the Nice area between 2005 and 2014. <i>Environmental Research</i> , <b>2020</b> , 188, 109681	7.9	1
157	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 84-96	4.5	9
156	In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 413-423	4.5	2
155	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. <i>Aids</i> , <b>2020</b> , 34, 599-608	3.5	4
154	Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 189-192	7.5	2
153	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , <b>2020</b> , 9, 6565-6575	4.8	11
152	Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , <b>2019</b> , 125, 2291-2299	6.4	10
151	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. <i>Health and Quality of Life Outcomes</i> , <b>2019</b> , 17, 115	3	9
150	Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 21,	6.3	4
149	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. <i>Cell Metabolism</i> , <b>2019</b> , 29, 1243-1257.e10	24.6	31
148	Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , <b>2019</b> , 33, 993-1000	3.5	5
147	LAMP2 expression dictates azacytidine response and prognosis in MDS/AML. <i>Leukemia</i> , <b>2019</b> , 33, 1501-1513	15.3	16
146	PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , <b>2019</b> , 20, 202-215	21.7	86
145	Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies. <i>Cancer Medicine</i> , <b>2018</b> , 7, 539-548	4.8	7

144	Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol. <i>Blood</i> , <b>2018</b> , 132, 4132-4132	2.2	
143	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology, the</i> , <b>2018</b> , 5, e403-e410	14.6	17
142	First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 310-312	4.4	1
141	Reply to C.F. Hess et al. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 374	2.2	
140	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , <b>2017</b> , 31, 2493-2501	3.5	33
139	FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. <i>Blood</i> , <b>2017</b> , 130, 1315-1326	2.2	59
138	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 216-221	4.4	77
137	VEGF, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. <i>Oncotarget</i> , <b>2017</b> , 8, 90808-90824	3.3	3
136	Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2425-8	1.9	
135	Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). <i>Annals of Oncology</i> , <b>2016</b> , 27, 719-24	10.3	62
134	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 51-7	4.4	149
133	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7518-7518	2.2	0
132	Chemotherapy and Interactions with Combination Antiretroviral Therapy <b>2016</b> , 207-214		1
131	Diffuse Large B-Cell Lymphoma <b>2016</b> , 39-65		0
130	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. <i>Oncotarget</i> , <b>2016</b> , 7, 83987-84002	3.3	14
129	Mobile applications in oncology: is it possible for patients and healthcare professionals to easily identify relevant tools?. <i>Annals of Medicine</i> , <b>2016</b> , 48, 509-515	1.5	38
128	Central nervous system involvement in AIDS-related lymphomas. <i>British Journal of Haematology</i> , <b>2016</b> , 173, 857-66	4.5	14
127	Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score IB, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2028-36	2.2	88

126	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 197-203	7.1	72
125	Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment. <i>Expert Review of Hematology</i> , <b>2015</b> , 8, 205-16	2.8	2
124	High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 1469-75	11.6	34
123	GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-B-dependent induction of HIF-1. <i>Leukemia</i> , <b>2015</b> , 29, 1163-76	10.7	39
122	Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2025-31	1.9	4
121	Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. <i>Haematologica</i> , <b>2015</b> , 100, 1579-86	6.6	18
120	Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. <i>Annals of Oncology</i> , <b>2015</b> , 26, 958-966	10.3	57
119	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , <b>2015</b> , 126, 517-517 <sup>2</sup>	2.2	1
118	Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study. <i>Blood</i> , <b>2015</b> , 126, 577-577	2.2	34
117	ABVD (8 cycles) versus BEACOPP (4 escalated cycles $\pm$ baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1622-8	10.3	74
116	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1854-60	1.9	59
115	Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 773-80	1.9	58
114	Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3996-4003	2.2	64
113	Expression of activating receptors on natural killer cells from AIDS-related lymphoma patients. <i>AIDS Research and Therapy</i> , <b>2014</b> , 11, 38	3	4
112	Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA. <i>Lymphoma</i> , <b>2014</b> , 2014, 1-12		11
111	Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. <i>Oncotarget</i> , <b>2014</b> , 5, 4384-91	3.3	13
110	Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients. <i>Transfusion</i> , <b>2013</b> , 53, 115-22	2.9	3
109	Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 780-3	7.1	14

108	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 525-33	21.7	200
107	Blastic plasmacytoid dendritic cell neoplasm: a report of four cases and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, 1176-81	4.6	12
106	Personalized medicine in oncology: where have we come from and where are we going?. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 931-9	2.6	36
105	PET imaging <b>2013</b> , 96-108		
104	Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. <i>Haematologica</i> , <b>2013</b> , 98, 1726-31	6.6	94
103	AIDS-Related Lymphoma <b>2013</b> , 257-266		
102	Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 240-6	2.2	216
101	A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2013</b> , 163, 334-42	4.5	33
100	Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine. <i>Blood Cancer Journal</i> , <b>2013</b> , 3, e155	7	16
99	Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice. <i>Blood</i> , <b>2013</b> , 122, 2402-11	2.2	36
98	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. <i>Blood</i> , <b>2013</b> , 122, 3251-62	2.2	120
97	Lenalidomide In Combination With R-CHOP (R2-CHOP) In Patients With High Burden Follicular Lymphoma: Phase 2 Study. <i>Blood</i> , <b>2013</b> , 122, 248-248	2.2	6
96	Prognostic Impact Of Somatic NOTCH2 Mutation In Splenic Marginal Zone Lymphoma. <i>Blood</i> , <b>2013</b> , 122, 4247-4247	2.2	3
95	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. <i>Blood</i> , <b>2013</b> , 122, 764-764	2.2	7
94	Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2013</b> , 122, 1568-1568	2.2	
93	Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4462-9	2.2	194
92	Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4317-22	2.2	140
91	MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. <i>Blood</i> , <b>2012</b> , 119, 4619-24	2.2	123

90	High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 788-93	4.7	77
89	Relapses, treatments and new drugs. <i>Best Practice and Research in Clinical Haematology</i> , <b>2012</b> , 25, 49-60	4.2	9
88	Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2012</b> , 12, 151-4	2	14
87	Breast cancer among HIV infected individuals from the ONCOVIH study, in France: therapeutic implications. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 3335-41	7.5	16
86	Hodgkin lymphoma in patients with HIV infection: a review. <i>Current Hematologic Malignancy Reports</i> , <b>2012</b> , 7, 228-34	4.4	25
85	BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. <i>Oncotarget</i> , <b>2012</b> , 3, 490-501	3.3	66
84	ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup´ randomized phase III clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8002-8002	2.2	22
83	(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11, 212-8	2	50
82	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. <i>Lancet, The</i> , <b>2011</b> , 378, 1858-67	4.0	251
81	Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. <i>Current Opinion in Oncology</i> , <b>2011</b> , 23, 209-13	4.2	6
80	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. <i>Haematologica</i> , <b>2011</b> , 96, 1136-43	6.6	74
79	New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2011</b> , 86, 619-21	7.1	3
78	Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 1239-48	1.9	13
77	The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4079-87	2.2	207
76	Quality of life following treatment for B-cell lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2011</b> , 11, 523-32	2.2	1
75	Pneumoblastoma: a rare lung tumour occurring as a long-term complication after allogeneic haematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2010</b> , 45, 197-8	4.4	2
74	Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4184-90	2.2	1005
73	Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 1668-77	1.9	2



72	Hodgkin lymphoma in HIV positive patients. <i>Current HIV Research</i> , <b>2010</b> , 8, 141-6	1.3	11
71	Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2010</b> , 10, 262-9	2	43
70	Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 15, 78-85	4.7	73
69	Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naïve, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Cancer</i> , <b>2009</b> , 115, 1000-1006	6.4	14
68	Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2739-41	2.2	48
67	Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5573-9	2.2	100
66	Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1985-92	10.3	60
65	Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). <i>Cancer</i> , <b>2009</b> , 115, 4540-6	6.4	46
64	Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 549-55	3.5	15
63	Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 72, 10-20	7	46
62	Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 1160-70	21.7	80
61	High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 440-6	2.2	198
60	Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3614-20	2.2	118
59	Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. <i>Annals of Oncology</i> , <b>2008</b> , 19, 560-5	10.3	4
58	AIDS-related malignancies: state of the art and therapeutic challenges. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4834-42	2.2	92
57	Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1875-81	10.3	39
56	Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , <b>2008</b> , 111, 4463-70	2.2	237
55	Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. <i>Blood</i> , <b>2008</b> , 112, 4824-31	2.2	270

54	Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. <i>Haematologica</i> , <b>2008</b> , 93, 1837-42	6.6	79
53	VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. <i>Cancer</i> , <b>2008</b> , 112, 433-42	6.4	18
52	High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls.. <i>Blood</i> , <b>2008</b> , 112, 2191-2191	2.2	1
51	High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls. <i>Cancer</i> , <b>2007</b> , 109, 60-7	6.4	13
50	The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. <i>Cancer</i> , <b>2007</b> , 110, 1361-9	6.4	64
49	Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations. <i>Bone Marrow Transplantation</i> , <b>2007</b> , 40, 831-5	4.4	44
48	Modern management of non-Hodgkin lymphoma in HIV-infected patients. <i>British Journal of Haematology</i> , <b>2007</b> , 136, 685-98	4.5	49
47	Image-guided core-needle biopsy of peripheral lymph nodes allows the diagnosis of lymphomas. <i>European Radiology</i> , <b>2007</b> , 17, 843-9	8	45
46	CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 787-92	2.2	200
45	Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1732-40	2.2	88
44	A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 691-8	1.9	2
43	Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , <b>2007</b> , 109, 2183-9	2.2	59
42	R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.. <i>Blood</i> , <b>2007</b> , 110, 517-517	2.2	10
41	Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapy. <i>Clinical Biochemistry</i> , <b>2006</b> , 39, 86-90	3.5	9
40	Managing large cell lymphoma. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 4, iv8-11	10.3	5
39	AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. <i>Blood</i> , <b>2006</b> , 107, 3832-40	2.2	114
38	Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Blood</i> , <b>2006</b> , 107, 4636-42	2.2	42
37	Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Blood</i> , <b>2006</b> , 108, 2510-4	2.2	198



36	Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. <i>Blood</i> , <b>2006</b> , 108, 4163-9	2.2	103
35	Angioimmunoblastic T-Cell Lymphoma: A Clinicopathologic Study of 158 Patients Treated in GELA (Groupe d'Etude des Lymphomes de l'Adulte) Trials.. <i>Blood</i> , <b>2006</b> , 108, 397-397	2.2	1
34	Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , <b>2006</b> , 91, 715-6	6.6	21
33	Non-Hodgkin's lymphoma of the breast: a report of 19 cases and a review of the literature. <i>Clinical Lymphoma and Myeloma</i> , <b>2005</b> , 6, 37-42		30
32	Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. <i>Oncology Reports</i> , <b>2005</b> , 14, 513	3.5	1
31	Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. <i>Experimental Hematology</i> , <b>2005</b> , 33, 894-900	3.1	55
30	Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. <i>Cancer</i> , <b>2005</b> , 104, 2735-42	6.4	19
29	Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 1555-63		87
28	Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. <i>Blood</i> , <b>2004</b> , 103, 1222-8	2.2	114
27	Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2826-34	2.2	53
26	All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Annals of Oncology</i> , <b>2004</b> , 15, 1790-7	10.3	49
25	FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). <i>Leukemia</i> , <b>2004</b> , 18, 2038-40	10.7	10
24	Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. <i>Laboratory Investigation</i> , <b>2004</b> , 84, 1512-9	5.9	82
23	Improving Second-Line Therapy in Aggressive Non-Hodgkin's Lymphoma. <i>Seminars in Oncology</i> , <b>2004</b> , 31 Suppl 2, 12-16	5.5	14
22	Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. <i>Blood</i> , <b>2004</b> , 103, 695-7	2.2	54
21	Follicular lymphoma international prognostic index. <i>Blood</i> , <b>2004</b> , 104, 1258-65	2.2	1348
20	T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1271-7	2.2	47
19	Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework. <i>Medical Decision Making</i> , <b>2003</b> , 23, 54-66	2.5	12

18	Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , <b>2003</b> , 30, 28-33	5.5	14
17	Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). <i>Blood</i> , <b>2003</b> , 101, 4279-84	2.2	428
16	Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4402-6	2.2	180
15	Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 467-75	2.2	154
14	Impact of high-dose chemotherapy on peripheral T-cell lymphomas. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1426-7	2.2	21
13	High-dose therapy for indolent lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2002</b> , 41, 225-39	7	10
12	Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. <i>British Journal of Haematology</i> , <b>2002</b> , 118, 210-7	4.5	24
11	Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. <i>British Journal of Haematology</i> , <b>2002</b> , 119, 726-39	4.5	91
10	CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. <i>Blood</i> , <b>2002</b> , 99, 2940-7	2.2	101
9	Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients. <i>Annals of Oncology</i> , <b>2001</b> , 12, 1749-55	10.3	12
8	Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study. <i>American Journal of Surgical Pathology</i> , <b>2001</b> , 25, 297-306	6.7	33
7	Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 1309-15	2.2	51
6	Myelodysplasia after autotransplantation. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3446-7	2.2	7
5	A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. <i>JAMA - Journal of the American Medical Association</i> , <b>2000</b> , 283, 2816-21	27.4	170
4	Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. <i>Leukemia</i> , <b>1998</b> , 12, 213-9	10.7	27
3	A multivariate analysis of the survival of patients with aggressive lymphoma. <i>Cancer</i> , <b>1998</b> , 82, 1952-1966	6.4	22
2	A multivariate analysis of the survival of patients with aggressive lymphoma <b>1998</b> , 82, 1952		7
1	Lymphoplasmocytic malignant lymphoma presenting with spinal epidural involvement: four reports of this uncommon lesion. <i>American Journal of Hematology</i> , <b>1995</b> , 50, 316-7	7.1	2

